Poor Outcomes Related to Anterior Extension of Large Hemispheric Infarction: Topographic Analysis of GAMES-RP Trial MRI Scans.


Journal

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 03 05 2019
revised: 09 10 2019
accepted: 15 10 2019
pubmed: 4 12 2019
medline: 19 2 2020
entrez: 3 12 2019
Statut: ppublish

Résumé

We aimed to assess the correlation of lesion location and clinical outcome in patients with large hemispheric infarction (LHI). We analyzed admission MRI data from the GAMES-RP trial, which enrolled patients with anterior circulation infarct volumes of 82-300 cm We included 83 patients with known 3-month modified Rankin scale (mRS). In voxel-wise analysis, there was significant correlation between admission infarct lesions involving the anterior cerebral artery (ACA) territory and its middle cerebral artery (MCA) border zone with both higher 3-month mRS and post-stroke day 3 and 7 National Institutes of Health Stroke Scale (NIHSS) total score and arm/leg subscores. Higher NIHSS total scores from admission through poststroke day 2 correlated with left MCA infarcts. In multivariate analysis, ACA territory infarct volume (P = .001) and admission NIHSS (P = .005) were independent predictors of 3-month mRS. Moreover, in a subgroup of 36 patients with infarct lesions involving right MCA-ACA border zone, intravenous (IV) glibenclamide (BIIB093; glyburide) treatment was the only independent predictor of 3-month mRS in multivariate regression analysis (P = .016). Anterior extension of LHI with involvement of ACA territory and ACA-MCA border zone is an independent predictor of poor functional outcome, likely due to impairment of arm/leg motor function. If confirmed in larger cohorts, infarct topology may potentially help triage LHI patients who may benefit from IV glibenclamide. URL: https://www.clinicaltrials.gov. Unique identifier: NCT01794182.

Sections du résumé

BACKGROUND BACKGROUND
We aimed to assess the correlation of lesion location and clinical outcome in patients with large hemispheric infarction (LHI).
METHODS METHODS
We analyzed admission MRI data from the GAMES-RP trial, which enrolled patients with anterior circulation infarct volumes of 82-300 cm
RESULTS RESULTS
We included 83 patients with known 3-month modified Rankin scale (mRS). In voxel-wise analysis, there was significant correlation between admission infarct lesions involving the anterior cerebral artery (ACA) territory and its middle cerebral artery (MCA) border zone with both higher 3-month mRS and post-stroke day 3 and 7 National Institutes of Health Stroke Scale (NIHSS) total score and arm/leg subscores. Higher NIHSS total scores from admission through poststroke day 2 correlated with left MCA infarcts. In multivariate analysis, ACA territory infarct volume (P = .001) and admission NIHSS (P = .005) were independent predictors of 3-month mRS. Moreover, in a subgroup of 36 patients with infarct lesions involving right MCA-ACA border zone, intravenous (IV) glibenclamide (BIIB093; glyburide) treatment was the only independent predictor of 3-month mRS in multivariate regression analysis (P = .016).
CONCLUSIONS CONCLUSIONS
Anterior extension of LHI with involvement of ACA territory and ACA-MCA border zone is an independent predictor of poor functional outcome, likely due to impairment of arm/leg motor function. If confirmed in larger cohorts, infarct topology may potentially help triage LHI patients who may benefit from IV glibenclamide.
CLINICAL TRIAL REGISTRATION BACKGROUND
URL: https://www.clinicaltrials.gov. Unique identifier: NCT01794182.

Identifiants

pubmed: 31787498
pii: S1052-3057(19)30572-5
doi: 10.1016/j.jstrokecerebrovasdis.2019.104488
pmc: PMC8820410
mid: NIHMS1774072
pii:
doi:

Substances chimiques

Hypoglycemic Agents 0
Glyburide SX6K58TVWC

Banques de données

ClinicalTrials.gov
['NCT01794182']

Types de publication

Comparative Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

104488

Subventions

Organisme : NINR NIH HHS
ID : R01 NR018335
Pays : United States
Organisme : NINDS NIH HHS
ID : U24 NS107136
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS099209
Pays : United States
Organisme : NIA NIH HHS
ID : K76 AG059992
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS076597
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG021342
Pays : United States
Organisme : NINDS NIH HHS
ID : U24 NS107215
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS106513
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS110721
Pays : United States

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Références

Lancet Neurol. 2016 Oct;15(11):1160-9
pubmed: 27567243
Stroke. 2018 Jun;49(6):1457-1463
pubmed: 29789393
Neuroimage. 2014 May 15;92:381-97
pubmed: 24530839
J Neuroimaging. 2017 Mar;27(2):227-231
pubmed: 27593522
PLoS One. 2013 Aug 07;8(8):e71141
pubmed: 23951094
Arch Neurol. 1996 Apr;53(4):309-15
pubmed: 8929152
Stroke. 2014 Apr;45(4):1222-38
pubmed: 24481970
Neurocrit Care. 2016 Feb;24(1):132-9
pubmed: 26268138
Neurocrit Care. 2014 Apr;20(2):319-33
pubmed: 24132564
J Stroke Cerebrovasc Dis. 2018 Apr;27(4):936-944
pubmed: 29198948
Eur J Neurol. 2013 Jan;20(1):153-9
pubmed: 22834894
Stroke. 2014 Jun;45(6):1695-702
pubmed: 24781084
Neurology. 2012 Jun 5;78(23):1853-9
pubmed: 22573641
AJNR Am J Neuroradiol. 2017 Jan;38(1):58-63
pubmed: 27758775
Neuroimage. 2010 Jan 1;49(1):127-33
pubmed: 19660556
PLoS One. 2015 May 11;10(5):e0125687
pubmed: 25961856
Neurology. 2018 Dec 4;91(23):e2163-e2169
pubmed: 30446594
Lancet Neurol. 2018 Dec;17(12):1109-1120
pubmed: 30509695
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
AJNR Am J Neuroradiol. 2010 Oct;31(9):1661-8
pubmed: 20488905

Auteurs

Seyedmehdi Payabvash (S)

Division of Neuroradiology, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.

Guido J Falcone (GJ)

Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.

Gordon K Sze (GK)

Division of Neuroradiology, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut.

Abhi Jain (A)

College of Medicine, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania.

Lauren A Beslow (LA)

Division of Neurology, Children's Hospital of Philadelphia, Departments of Neurology and Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

Nils H Petersen (NH)

Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut.

Kevin N Sheth (KN)

Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, New Haven, Connecticut. Electronic address: kevin.sheth@yale.edu.

W Taylor Kimberly (WT)

Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH